eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
1/2023
vol. 25
 
Share:
Send email
Share:
Review paper

Poly(Ethylene Glycol)-Poly(Lactic Acid) TLR7 Agonist as a Novel HBsAg Immune Response Stimulant

Bryan Gervais de Liyis
1
,
David Christopher Tjandra
1
,
Viona Mareska
1
,
Jane Carissa Sutedja
1
,
Cokorda Agung Wahyu Purnamasidhi
2
,
Cokorde Istri Yuliandari Krisnawadani K.
2

  1. Faculty of Medicine, Udayana University, Bali, Indonesia
  2. Department of Internal Medicine, Faculty of Medicine, Udayana University/ Udayana University Hospital, Bali, Indonesia
Family Medicine & Primary Care Review 2023; 25(1): 87–92
DOI: https://doi.org/10.5114/fmpcr.2023.125499
Online publish date: 2023/03/31
Article file
- 15 FM&PCR 1 23 - R - Gervais de Liyis - Poly(Ethylene) - 1244.pdf  [0.83 MB]
Get citation
 
PlumX metrics:
 
1. Division of Viral Hepatitis NC for H. National Progress Report 2025 Goal: Reduce HBV Deaths. Centers for Disease Control and Prevention; 2021. Available from URL: https://www.cdc.gov/hepatitis/policy/strategicplansrpts.html.
2. Mehta P, Reddivari AKR. Hepatitis. StatPearls Publishing; 2021. Available from URL: https://www.ncbi.nlm.nih.gov/books/NBK554549/.
3. Lim JK, Nguyen MH, Kim WR, et al. Prevalence of Chronic Hepatitis B Virus Infection in the United States. Am J Gastroenterol 2020; 115: 1429–1438.
4. Zheng Y, Wu J, Ding C, et al. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study. Virol J 2020; 17(1): 132, doi: 10.1186/s12985-020-01393-z.
5. Alberts CJ, Clifford GM, Georges D, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol 2022; 7: 724–735.
6. Muljono DH. Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian J Hepato-Gastroenterology 2017; 7: 55.
7. Tripathi N, Mousa OY. Hepatitis B. StatPearls Publishing; 2022. Available from URL: https://www.ncbi.nlm.nih.gov/books/NBK555945/.
8. Smith AAA, Gale EC, Roth GA, et al. Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment. Biom-acromolecules 2020; 21: 3704–3712.
9. Hu Y, Tang L, Zhu Z, et al. A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model. J Transl Med 2020; 18: 112.
10. Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. Biomed Res Int 2021; 2021: 1157023, doi: 10.1155/2021/1157023.
11. Chi H, Li C, Zhao FS, et al. Anti-tumor activity of toll-like receptor 7 agonists. Front Pharmacol 2017; 8: 304.
12. Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med 2014; 4(12): a024935, doi: 10.1101/cshperspect.a024935.
13. Higgins PA. Hepatitis B Virus. J Am Acad Physician Assist 2016; 29: 48–49, doi: 10.1097/01.JAA.0000484310.19556.82.
14. Soi V, Daifi C, Yee J, et al. Pathophysiology and Treatment of Hepatitis B and C Infections in Patients with End-Stage Renal Disease. Adv Chronic Kidney Dis 2019; 26: 41–50.
15. Nguyen MH, Wong G, Gane E, et al. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev 2020; 33: e00046-19.
16. Pardee M. Diagnosis and Management of Hepatitis B and C. Nurs Clin North Am 2019; 54: 277–284.
17. Yuen M-F, Chen D-S, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Prim 2018; 4: 18035.
18. Herrscher C, Roingeard P, Blanchard E. Hepatitis B Virus Entry into Cells. Cells 2020; 9(6): 1486, doi: 10.3390/cells9061486.
19. Chakravarty R, Das D, Sarkar N, et al. Role of TLR7 Agonist in Hepatitis B Infection: An In Vitro Study. J Clin Exp Hepatol 2014; 4: S20.
20. Venkatakrishnan B, Zlotnick A. The Structural Biology of Hepatitis B Virus: Form and Function. Annu Rev Virol 2016; 3: 1–28.
21. Boni C, Vecchi A, Rossi M, et al. TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients with Chronic Hepati-tis B Treated with Nucleos(T)Ide Analogues. Gastroenterology 2018; 154: 1764–1777.
22. Smith AAA, Gale EC, Roth GA, et al. Supporting information Nanoparticles presenting potent TLR 7/8 agonists enhance anti-PD-L1 immunotherapy in cancer treatment. Biomacromolecules 2020; 21(9): 3704–3712, doi: 10.1021/acs.biomac.0c00812.
23. Hu K, Li J, Shen Y, et al. Lactoferrin-conjugated PEG–PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations.
24. J Control Release 2009; 134: 55–61.
25. Ghasemi R, Abdollahi M, Emamgholi Zadeh E, et al. mPEG-PLA and PLA-PEG-PLA nanoparticles as new carriers for delivery of recombinant human Growth Hormone (rhGH). Sci Reports 2018; 8: 1–13.
26. Wu J, Zhao J, Zhang B, et al. Polyethylene glycol–polylactic acid nanoparticles modified with cysteine–arginine–glutamic acid–lysine–alanine fibrin-homing peptide for glioblastoma therapy by enhanced retention effect. Int J Nanomedicine 2014; 9: 5261–5271.
27. Taha MA, Singh SR, Dennis VA. Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide. Nanotechnology 2012; 23(32): 325101, doi: 10.1088/0957-4484/23/32/325101.
28. Dixit S, Singh SR, Yilma AN, et al. Poly (lactic acid)-poly (ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice. Nanomedicine 2014; 10: 1311.
29. Fairley SJ, Singh SR, Yilma AN, et al. Chlamydia trachomatis recombinant MOMP encapsulated in PLGAnanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: adesirable candidate nanovaccine. Int J Nanomedicine 2013; 8: 2085.
30. Fosdick A, Zheng J, Pflanz S, et al. Pharmacokinetic and pharmacodynamic properties of gs-9620, a novel toll-like receptor 7 agonist, demonstrate interfer-on-stimulated gene induction without detectable serum interferon at low oral dosess. J Pharmacol Exp Ther 2014; 348: 96–105.
31. Haegebaert RMS, Kempers M, Ceelen W, et al. Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer. Eur
32. J Pharm Biopharm 2022; 172: 16–30, doi: 10.1016/j.ejpb.2022.01.002.
33. Bertrand N, Grenier P, Mahmoudi M, et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat Commun 2017; 8: 777.
34. Johnstone TC, Kulak N, Pridgen EM, et al. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano 2013; 7: 5675–5683.
35. Almoustafa HA, Alshawsh MA, Chik Z. Technical aspects of preparing PEG-PLGA nanoparticles as carrier for chemotherapeutic agents by nanoprecipitation method. Int J Pharm 2017; 533: 275–284.
36. Yin Q, Luo W, Mallajosyula VVA, et al. A universal TLR7-nanoparticle adjuvant promotes broad immune responses against heterologous strains of Influenza and SARS-CoV-2. Nat Mater 2023, doi: 10.1038/s41563-022-01464-2.
37. Xu N, Yao H-P, Lv G-C, et al. Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B. In-flamm Res 2012; 61: 997–1004.
38. Das D, Sengupta I, Sarkar N, et al. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line. BMC Infect Dis 2017; 17: 76.
39. Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144: 1508–1517.
40. Wildum S, Korolowicz KE, Suresh M, et al. Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks with Chronic Hepatitis B. Front Immunol 2022; 13: 884113.
41. Isogawa M, Robek MD, Furuichi Y, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269–7272.
42. Ezzikouri S, Hoque Kayesh ME, Benjelloun S, et al. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vac-cines (Basel) 2020; 8(2): 216, doi: 10.3390/vaccines8020216.
43. Mullins SR, Vasilakos JP, Deschler K, et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. J Immunother Cancer 2019; 7: 244.
44. Lucifora J, Bonnin M, Aillot L, et al. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Sci Rep 2018; 8: 5390.
45. Schlaepfer E, Speck RF. Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering. PLoS ONE 2008; 3: e1999.
46. Borducchi EN, Liu J, Nkolola JP, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 2018; 563: 360–364.
47. Wu S, Wang W, Gao Y. Natural killer cells in hepatitis B virus infection. Brazilian J Infect Dis 2015; 19: 417–425.
48. Marotel M, Villard M, Drouillard A, et al. Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion. Elife 2021; 10: e60095, doi: 10.7554/eLife.60095.
49. Funk E, Kottilil S, Gilliam B, et al. Tickling the TLR7 to cure viral hepatitis. J Transl Med 2014; 12: 129.
50. Kayesh ME, Kohara M, Tsukiyama-Kohara K. Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview. Int J Mol Sci 2021; 22(19): 10462, doi: 10.3390/ijms221910462.
Copyright: © 2023 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.